The Endpoints 100: What are execs saying now?

Thursday, December 11, 2025  |  12:00 PM – 1:00 PM ET

Back in May, our Endpoints 100 survey captured biotech at a low point — IPOs were essentially dead, confidence in venture funding hit record lows, and execs were bracing for FDA disruptions as the agency underwent its biggest shakeup in years.

Now we're checking back in. Have the green shoots in deal flow and regulatory clarity translated into renewed optimism, or are leaders still hunkered down waiting for the storm to pass?

Editor-in-Chief John Carroll will convene a panel of biopharma leaders to break down our latest survey results and explore what the data reveals about where the industry stands as 2025 draws to a close. Join us.

SPONSORED BY